S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) Director S. Louise Phanstiel bought 50,407 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were bought at an average price of $4.80 per share, for a total transaction of $241,953.60. Following the completion of the transaction, the director directly owned 233,951 shares of the company’s stock, valued at $1,122,964.80. This represents a 27.46% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

S. Louise Phanstiel also recently made the following trade(s):

• On Friday, February 27th, S. Louise Phanstiel purchased 48,000 shares of Myriad Genetics stock. The stock was bought at an average price of $4.66 per share, with a total value of $223,680.00.
• On Wednesday, February 25th, S. Louise Phanstiel acquired 6,100 shares of Myriad Genetics stock. The stock was bought at an average cost of $4.74 per share, for a total transaction of $28,914.00.

Myriad Genetics Trading Down 5.1%

Shares of NASDAQ:MYGN opened at $4.61 on Friday. The stock has a 50 day moving average of $5.61 and a 200 day moving average of $6.60. The company has a market cap of $431.08 million, a PE ratio of -1.17 and a beta of 1.90. Myriad Genetics, Inc. has a 12-month low of $3.76 and a 12-month high of $11.44. The company has a current ratio of 2.49, a quick ratio of 2.12 and a debt-to-equity ratio of 0.33.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.06. The business had revenue of $209.80 million for the quarter, compared to the consensus estimate of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.03 earnings per share. As a group, equities research analysts expect that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Key Headlines Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open‑market purchases totaling roughly 104,507 shares across Feb. 25–27 (average prices ~ $4.66–$4.80), increasing her stake substantially — a strong signal of insider confidence that can attract buyers. SEC Form 4 filing
• Positive Sentiment: Zacks Research upgraded MYGN from “strong sell” to “hold,” which can reduce model-driven selling and support demand from investors using Zacks screens. Zacks.com
• Neutral Sentiment: Media coverage (TipRanks, MarketBeat, InsiderTrades) amplified the insider activity — this typically increases short‑term volume and retail attention but does not change fundamentals by itself. TipRanks article
• Negative Sentiment: Company updated Q1 FY2026 revenue guidance to $200.0M–$203.0M vs. consensus ~$203.5M and did not provide EPS guidance — the slightly lower top‑line outlook and missing EPS figure create short‑term uncertainty that can pressure the shares. (Company guidance release)
• Negative Sentiment: Recent analyst moves include price‑target cuts (e.g., UBS and Wells Fargo lowering targets to ~$6.00) and mixed ratings — these downward revisions contribute to bearish near‑term sentiment despite some longer‑term analyst support. MarketBeat analyst summary

Institutional Investors Weigh In On Myriad Genetics

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its position in Myriad Genetics by 2.4% during the fourth quarter. Invesco Ltd. now owns 507,180 shares of the company’s stock valued at $3,119,000 after purchasing an additional 12,026 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Myriad Genetics by 62.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 26,886 shares of the company’s stock valued at $165,000 after buying an additional 10,359 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Myriad Genetics by 103.8% in the 4th quarter. Vestal Point Capital LP now owns 1,223,000 shares of the company’s stock valued at $7,521,000 after acquiring an additional 623,000 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in Myriad Genetics in the fourth quarter worth about $276,000. Finally, Oxford Asset Management LLP purchased a new position in Myriad Genetics in the fourth quarter worth about $143,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wells Fargo & Company decreased their price target on Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Piper Sandler cut their target price on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Finally, UBS Group cut their price objective on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday. Four analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.17.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.